Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Gastric06: T-DXd in Advanced Gastric/GEJ Cancer
NCT04989816Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by AstraZeneca. Primary endpoints: Confirmed Objective Response Rate up to 19.3 months and Best Objective Response Rate up to 19.3 months. Started Aug 2021; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04989816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989816.